Frenelle Pharma is a deploying our Faros long-acting injectable technology across multiple therapeutic areas with active programs in opioid use disorder ($2B opportunity backed by Mayo Ventures) and inhalation (dry powder inhaler co-development with leading inhalation company); and we have opportunities in cardio-metabolic (long-acting GLP-1), neuropathic pain (injectable for sciatica) and ophthalmology (supra-choroidal injectable via 30G needle). Faros is a novel LAI platform that enables ultra-high concentration injections via small gauge needles with dosing intervals from weeks to months. The platform has been clinically proven in a Phase 2 lumbar radicular pain study via epidural injection.

We are adving FRN01, monthly injectable buprenorphine for opioid use disorder, at Frenelle PBC, our public benefit corporation subsidiary backed by Mayo Ventures. And, we are advancing ANM02, 90-day injectable PPA for canine urinary incontinence, at Anumio, our companion animal subsidiary.